2 completed, 1 active not recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Autosomal Dominant Hypocalcemia (ADH): new trials by email Literature Review of Autosomal Dominant Hypocalcemia (ADH) trials Research Report on Autosomal Dominant Hypocalcemia (ADH)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Encaleret, Standard of Care - Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 67 | 2023-01-06 | 2026-07-29 |
| Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1 Encaleret - Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2 | Completed | Calcilytix Therapeutics, Inc., a BridgeBio company | 13 | 2020-09-20 | 2024-11-19 |
| A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations NPSP795 - Autosomal Dominant Hypocalcemia (ADH) | Phase 2 | Completed | Shire | 7 | 2014-07-18 | 2021-08-09 |
Hypercalciuric Hypocalcemia, Familial (3) · Hypocalcemia (2) · Hypoparathyroidism (2) · Calcium Metabolism Disorders (1) · Hypercalciuria (1) · Metabolic Diseases (1) · Muscular Diseases (1) · Musculoskeletal Abnormalities (1) · Musculoskeletal Diseases (1) · Nephrocalcinosis (1) · Nephrolithiasis (1)
Endocrine System Diseases (2) · Nutritional and Metabolic Diseases (2) · Parathyroid Diseases (2) · Water-Electrolyte Imbalance (2) · Calcinosis (1) · Calcium Metabolism Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1)
Standard of Care (1)
Calcilytix Therapeutics, Inc., a BridgeBio company (2) · Shire (1)
United States (3) · Australia (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · United Kingdom (1)